Chapter 18. Use of Vasculature-disrupting Agents in Non-Oncology Indications

  1. Dietmar W. Siemann3,4
  1. Joseph C. Randall1 and
  2. Scott L. Young2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch18

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Randall, J. C. and Young, S. L. (2006) Use of Vasculature-disrupting Agents in Non-Oncology Indications, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch18

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    Preclinical Research, OXiGENE, Inc., 230 3rd Avenue, Waltham, MA 02451, USA

  2. 2

    Clinical Affairs, OXiGENE, Inc., 230 3rd Avenue, Waltham, MA 02451, USA

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436

SEARCH

Keywords:

  • pro-angiogenic phenotype;
  • aberrant vascular phenotype;
  • vascular-disrupting agents - anti-mitotic, anti-proliferative and antivascular effects;
  • Age-related macular degeneration (AMD);
  • myopic macular degeneration;
  • retinopathy of prematurity (ROP);
  • proliferative diabetic retinopathy;
  • pediatric hemangiomas;
  • abnormally elicited neovascular development - use for VDAs

Summary

This chapter contains sections titled:

  • Background

  • Age-related macular degeneration (AMD)

  • Myopic macular degeneration

  • Retinopathy of prematurity

  • Proliferative diabetic retinopathy

  • Pediatric hemangiomas

  • Arthritis

  • Psoriasis

  • Conclusions

  • References